Table 3.
Clinical and pathological characteristics of 48 HGSOC patients and their association with FXYD5 protein expression evaluated by immunohistochemistry
| FXYD5 protein expression | ||||||
|---|---|---|---|---|---|---|
| Variable | No. | Score 1 + N° (%) | Score 2 + N° (%) | Score 3 + N° (%) | p-valuea | |
| Age at diagnosis | ||||||
| ≥65 | 29 | 14 (48) | 10 (35) | 5 (17) | 0.585 | |
| <65 | 19 | 11 (58) | 5 (26) | 3 (16) | ||
| Menopause | ||||||
| Post | 40 | 21 (53) | 13 (32) | 6 (15) | 0.749 | |
| Pre | 8 | 4 (50) | 2 (25) | 2 (25) | ||
| FIGO stage | ||||||
| I-II | 4 | 3 (75) | 1 (25) | 0 | I–II vs III–IV | 0.294 |
| III | 32 | 15 (47) | 11 (34) | 6 (19) | I–II–III vs IV | 0.704 |
| IV | 12 | 7 (58) | 3 (25) | 2 (17) | III vs IV | 0.574 |
| Residual tumour (cm) | ||||||
| TR > 0 | 35 | 17 (49) | 11 (31) | 7 (20) | 0.338 | |
| TR = 0 | 13 | 8 (61) | 4 (31) | 1 (8) | ||
| Lymph nodal involvement | ||||||
| Pos | 12 | 6 (50) | 3 (25) | 3 (25) | 0.511 | |
| Neg | 14 | 8 (57) | 5 (36) | 1 (7) | ||
| Unknown | 22 | |||||
| Peritoneal cytology | ||||||
| Pos | 42 | 21 (50) | 13 (31) | 8 (19) | 0.182 | |
| Neg | 5 | 3 (60) | 2 (40) | 0 | ||
| Unknown | 1 | |||||
| Platinum response | ||||||
| Resistant | 26 | 11 (42) | 8 (31) | 7 (27) | R vs S | 0.049 |
| Sensitive | 19 | 13 (69) | 5 (26) | 1 (5) | R vs S + PS | 0.049 |
| Part Sens | 2 | 1 (50) | 1 (50) | 0 | ||
| Unknown | 1 | |||||
| Relapse/progression | ||||||
| Yes | 41 | 19 (46) | 14 (34) | 8 (20) | 0.053 | |
| No | 7 | 6 (86) | 1 (14) | 0 | ||
| Overall Survival (months) | ||||||
| OS < 36 | 30 | 11 (36.5) | 11 (36.5) | 8 (33) | 0.003 | |
| OS > 84 | 18 | 14 (78) | 4 (22) | 0 | ||
Bold type has been used for statistically significant results
aMann–Whitney test